一种新型抗疟疾药物,可以抑制Plasmodium falciparum中的蛋白质合成
Patricia Bravo1,2, Eleonora Diamanti3, Mostafa M Hamed3
1Medical Parasitology and Infection Biology, Swiss Tropical and Public Health Institute, Kreuzstrasse 2, Allschwil, 4123, Switzerland.
Angewandte Chemie (International ed. in English)
|October 21, 2025
概括
一种新型化合物,31号,显示出强大的抗疟疾活性,对抗菌和一种新的作用机制. 这一发现为开发下一代抗疟疾药物提供了有希望的候选人.
科学领域:
- 药用化学 医学化学
- 寄生虫学的寄生虫学
- 药物发现 药物发现 药物发现
背景情况:
- 对现有的抗疟疾药物的耐药性需要新的化合物.
- 迫切需要新的抗疟疾药物,具有独特的作用机制.
研究的目的:
- 为了识别和描述新的抗疟疾化合物.
- 研究一种新型化合物类的作用机制和电阻.
主要方法:
- 复合物选和表征 复合物选和表征 复合物选和表征
- 抗性选择研究.
- 在CRISPR/Cas9基因编辑中.
- 蛋白质组学分析.
主要成果:
- 化合物31,一种2-基胺,显示出对血和性阶段的Plasmodium falciparum有强烈活性.
- 在pfmdr1基因中发现了一种新的点突变,该突变被确定为对化合物31的耐药性原因.
- 化合物31通过与细胞质核糖体子单元结合来抑制蛋白质合成而起作用.
- 与一线抗疟药物没有观察到交叉耐药性.
结论:
- 化合物31代表了一种有前途的新化学型,用于抗疟疾药物开发.
- 已确定的作用机制和耐药性途径为未来的药物设计提供了宝贵的见解.
相关概念视频
Malaria
Malaria pathogenesis in humans reflects a delicate interplay between parasite biology and host response. Clinical illness reflects a host’s immune response to the parasite’s asexual replication cycle, which is often asymptomatic in individuals with partial immunity. From the parasite's perspective, transmission between mosquito and human with minimal host pathology is evolutionarily advantageous. Among the six Plasmodium species infecting humans, P. falciparum and P. vivax dominate in global...
Inhibitors of Bacterial Protein Synthesis
Aminoglycosides constitute a highly potent class of bactericidal antibiotics that exert their antimicrobial effects by targeting the bacterial ribosome, specifically disrupting protein synthesis. These polycationic molecules consist of amino-modified sugars linked via glycosidic bonds to an aminocyclitol core such as 2-deoxystreptamine or streptamine. Their strong positive charges facilitate tight binding to the negatively charged phosphate backbone of ribosomal RNA (rRNA), primarily at the 16S...
Inhibitors of Bacterial DNA Synthesis
Bacterial pathogens depend on precise and efficient DNA replication to sustain infection. Two type II topoisomerases—DNA gyrase and topoisomerase IV—are critical to this process, as they resolve DNA supercoiling and unlink chromosomes during replication. Fluoroquinolones, synthetic derivatives of quinolones, exploit this mechanism by stabilizing the transient DNA–enzyme cleavage complex, preventing strand religation, and causing lethal double-strand breaks. These antibiotics are selectively...
Inhibitors of Viral Protein Synthesis
Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
Anthelminthic Agents
Anthelmintic drugs differ significantly from antiparasitic therapies targeting protozoa, primarily due to differences in parasite biology. Whereas most protozoal treatments act on proliferating cells, anthelmintics are typically directed against mature, nonproliferative helminths. The therapeutic approach considers the helminth's reliance on neuromuscular coordination, glucose metabolism, and microtubular integrity for survival, reproduction, and localization within the host. Most anthelmintics...
Antiprotozoal Agents
Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...


